Core Viewpoint - The company Nanmo Biotechnology (688265.SH) announced a share transfer agreement involving significant shareholders due to funding needs, resulting in a change in ownership structure [1][2]. Group 1: Share Transfer Details - Shareholder Huirun Rongfeng will transfer 4,650,318 shares at a price of 27.369 CNY per share, representing 5.96% of the total share capital [1]. - Shareholder Kang Junningyuan will transfer 2,247,409 shares at the same price, representing 2.88% of the total share capital [1]. - Shareholder Zhangjiang Collective will transfer 1,782,000 shares at the same price, representing 2.29% of the total share capital [1]. Group 2: Post-Transfer Ownership Structure - After the transfer, Huirun Rongfeng and Zhangjiang Collective will no longer hold shares in the company, while Kang Junningyuan will hold 1,560,701 shares, representing 2.00% of the total share capital [2]. - Haowang Hezhong will hold 8,679,727 shares, representing 11.13% of the total share capital after the transfer [2].

Core Insights - The company reported a total revenue of 381 million yuan for 2024, reflecting a year-on-year growth of 4.01%, with significant disparities in performance across different business segments [1] Group 1: Business Performance - The standardized model business generated revenue of 165 million yuan, up 16.58% year-on-year, driven by increased demand from research clients and improved cost control, with project numbers surging by 45% [2] - The model breeding business saw a revenue decline of 8.60% to 90.06 million yuan, primarily due to a significant drop in project prices, which fell from 20,600 yuan per project in 2023 to 14,400 yuan in 2024, overshadowing the growth in project numbers [2] - The overseas business revenue reached 53.06 million yuan, marking a 31.88% increase, with a gross margin of 70.9%, significantly outperforming the domestic business gross margin of 41.66% [2] Group 2: Customer Structure - Industrial clients contributed higher gross margins in standardized models and efficacy evaluation services, with average prices of 115,200 yuan per project compared to 22,900 yuan for research clients, and gross margins for industrial clients being 10-30 percentage points higher [3] Group 3: Inventory and Capacity Management - The company reduced its inventory balance to 12.67 million yuan, a decrease of 19.95% year-on-year, with an inventory turnover rate of 15 times, significantly higher than industry peers [4] - The company operates nine production bases with a total capacity of 140,000 cages, with a current capacity utilization rate of 80%, and plans to reduce reliance on leasing through a planned expansion project [4]

Core Viewpoint - The company has responded to the regulatory inquiry regarding its 2024 annual report, addressing various aspects of its business performance and financial metrics, particularly focusing on revenue changes across different segments and the impact of market conditions on its operations [1][2]. Business Performance - In 2024, the company reported total revenue of 381.24 million yuan, with standardized model revenue at 164.77 million yuan, showing a year-on-year increase of 16.58%. However, model breeding revenue decreased by 8.60% to 90.06 million yuan, while drug efficacy evaluation and phenotypic analysis revenue increased by 7.14% to 53.20 million yuan [2][4]. - Domestic and international revenue were 325.43 million yuan and 53.06 million yuan respectively, with gross margins of 41.66% and 70.9%, indicating a 31.88% year-on-year growth in international revenue [2][4]. Revenue Analysis - The company conducted a volume and price analysis of revenue changes across different business segments, noting that the increase in standardized model revenue was due to a rise in project quantity, while the decline in customized model revenue was attributed to a decrease in project quantity [3][5]. - The company observed a general decline in project prices across all business types due to intensified market competition and increased customer price sensitivity [4][5]. Customer Segmentation - The customer base primarily consists of research and industrial clients, with research clients having a higher number but lower average transaction values compared to industrial clients [6][8]. - The revenue contribution from research clients and industrial clients remained stable year-on-year, with customized model business mainly serving research clients [6][8]. Gross Margin Comparison - The gross margin for standardized models increased by 7.26 percentage points, attributed to stable demand from research clients and improved cost control measures [7][9]. - The gross margin for breeding services decreased by 13.97 percentage points due to increased market competition and underutilization of breeding facilities, leading to higher unit costs [7][9]. International Business Growth - The company expanded its international market presence, resulting in significant revenue growth from overseas operations, with higher average sales prices compared to domestic sales [10][12]. - The gross margin for international sales was significantly higher than domestic sales, reflecting industry norms [10][12]. Inventory Management - As of the end of 2024, the company's inventory balance was 12.67 million yuan, a decrease of 19.95% year-on-year, with inventory turnover rates significantly higher than industry peers [19][21]. - The reduction in inventory was attributed to improved cost control, production efficiency, and the completion of long-term projects, particularly in drug efficacy evaluation and phenotypic analysis [19][21].

Core Viewpoint - The legal opinion letter from Shanghai Jintiancheng Law Firm addresses the inquiry regarding the information disclosure of Shanghai Southern Model Biotechnology Co., Ltd. for the 2024 annual report, particularly focusing on the implications of the termination of the concerted action relationship between the actual controllers of the company [1][2]. Group 1: Governance and Management Structure - The company has established a decision-making group but has not yet implemented it due to the postponement of the board of directors' re-election [6][9]. - The governance structure includes a shareholders' meeting as the authority, a board of directors responsible for executing resolutions, and a management team led by a general manager [7][9]. - The board consists of 9 directors, including 3 independent directors, and the chairman is elected by a majority of the board [6][8]. Group 2: Decision-Making Mechanism - The decision-making mechanism involves a voting system where each share has one vote, with ordinary resolutions requiring over 50% approval and special resolutions needing two-thirds [8][10]. - The board's decisions must be approved by a majority of directors, and any related party must abstain from voting on relevant matters [8][10]. - The company has established internal governance documents, including the Articles of Association and rules for shareholders' and board meetings, to ensure compliance with legal requirements [9][12]. Group 3: Compliance and Future Considerations - The company is in compliance with the Company Law, Securities Law, and relevant regulations, ensuring the protection of minority investors' interests [10][12]. - The decision-making group's operational effectiveness and its impact on governance cannot be assessed until it is formally established and operational [9][13]. - Future adjustments to the governance structure will depend on the outcomes of the board re-election and the decision on whether to retain the decision-making group [12][13].

国泰海通证券股份有限公司 关于上海南方模式生物科技股份有限公司 2024年年度报告的信息披露监管问询函的核查意见 上海证券交易所： 根据贵所《关于上海南方模式生物科技股份有限公司 2024 年年度报告的信 息披露监管问询函》（上证科创公函【2025】0168 号，以下简称"问询函"）的要 求，国泰海通证券股份有限公司（以下简称"保荐机构"或"国泰海通证券"） 作为上海南方模式生物科技股份有限公司（以下简称"南模生物"或"公司"） 首次公开发行股票并在科创板上市的保荐机构，对问询函进行了审慎核查，并回 复如下： 一、关于主营业务。 单位：万元 由上表可以看出，各业务类型项目单价 2024 年较 2023 年均有所下降。 标准化模型项目数量的增加引起该类业务收入增长，而定制化模型项目数量 的减少导致该类业务收入下降；模型繁育业务收入则由于项目单价的下降比例超 过了项目数量的增加比例，从而导致该类业务收入规模下降。 年报显示，（1）公司 2024 年营业收入 38,123.95 万元，其中标准化模型业 务收入 16,476.85 万元，同比增长 16.58%，模型繁育业务收入 9,005.94 万元， 同比下滑8. ...

关于上海南方模式生物科技股份有限公司 2024 年年度报告的信息披露监管问询函有关事项的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海南方模式生物科技股份有限公司 2024 年年度报告的信息披露监管问询函有关事项的 上海市锦天城律师事务所 法律意见书 致：上海南方模式生物科技股份有限公司 上海市锦天城律师事务所（以下简称"锦天城"或"本所"）接受上海南方 模式生物科技股份有限公司（以下简称"公司"或"南模生物"）的委托，就《关 于上海南方模式生物科技股份有限公司 2024 年年度报告的信息披露监管问询函》 （上证科创公函【2025】0168 号）（以下简称"《年报问询函》"）中所涉事 项进行核查，并出具法律意见书。 为出具本法律意见书，本所律师根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、 ...

关于上海证券交易所 《关于上海南方模式生物科技股份有限公司 2024 年年度报告的信息披露监管问询函》 有关财务问题回复的专项说明 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road, Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhepa.cn 关于上海证券交易所 《关于上海南方模式生物科技股份有限公司 2024 年年度报告的信息披露监管问询函》 有关财务问题回复的专项说明 中汇会专[2025]9724号 上海证券交易所: 由上海南方模式生物科技股份有限公司(以下简称公司或南模生物公司)转 来的贵所于 2025年5月27日下发的《关于上海南方模式生物科技股份有限公司 2024 年年度报告的信息披露监管问询函》(上证科创公函【2025】0168号,以下 简称问询函)奉悉。我们作为南模生物公司的年报会计师,对问询函中需要我们 回复的财务问题进行了审慎核查。现就问询函 ...

证券代码：688265 证券简称：南模生物 公告编号：2025-042 上海南方模式生物科技股份有限公司 关于 2024 年年度报告的信息披露监管问询函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海南方模式生物科技股份有限公司（以下简称"公司"）于 2025 年 5 月 27 日收到上海证券交易所《关于上海南方模式生物科技股份有限公司 2024 年年 度报告的信息披露监管问询函》（上证科创公函【2025】0168 号）（以下简称 "《问询函》"），公司就函件关注的相关问题逐项进行了认真的核查落实，现 就函件相关问题回复如下： 一、关于主营业务。 年报显示，（1）公司 2024 年营业收入 38,123.95 万元，其中标准化模型 业务收入 16,476.85 万元，同比增长 16.58%，模型繁育业务收入 9,005.94 万元， 同比下滑 8.60%，药效评价和表型分析业务收入 5,320.49 万元，同比增长 7.14%； （2）从客户类型来看，公司客户主要包括科研和工业客户；（3）2024 年度， ...

证券代码：688265 证券简称：南模生物 公告编号：2025-040 上海南方模式生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 本次股票上市流通总数为28,575,000股。 ? 本次股票上市流通日期为2025 年 6 月 30 日。 （因 2025 年 6 月 28 日为非交 易日，故顺延至下一交易日） 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2021 年 11 月 2 日出具的《关于同意上海南 方模式生物科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕 有限公司（以下简称"公司"或"南模生物"）首次向社会公众公开发行人民币普通股 （A 股）股票 19,490,900 股，并于 2021 年 12 月 28 日在上海证券交易所科创板上 市，发行完成后总股本为 77,963,513 股，其中限售股 60,340,234 股，占公司总股 本的 77.40%，无限售条件的流通股为 ...

上海市锦天城律师事务所 关于上海南方模式生物科技股份有限公司 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 上海市锦天城律师事务所 法律意见书 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务管 理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行了法 定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事项进行 了必要的核查和验证，核查了本所认为出具该法律意见书所需的相关文件、资料， 并参加了公司本次股东大会的全过程。本所保证本法律意见书所认定的事实真实、 准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者 重大遗漏，并愿意承担相应法律责任。 本法律意见书仅供本次股东大会之目的使用。本所律师同意将本法律意见书随 南模生物本次股东大会其他信息披露资料一并公告。 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海南方模式生物科技股份有限公司 法律意见书 致：上海南方模式生物科技股份有限公司 根据《中华人民 ...